
VANI Stock Forecast & Price Target
VANI Analyst Ratings
Bulls say
Vivani Medical Inc. is positioned favorably in the biopharmaceutical market due to its proprietary NanoPortal technology, which facilitates the sustained delivery of medications for chronic diseases. The company’s candidate NPM-139 shows promising results, particularly in improving the safety and tolerability profile of existing therapies like semaglutide, with reported patient outcomes indicating an approximate 20% weight loss maintained for over six months. Given the encouraging data supporting NPM-139's advancement into clinical development, the company's prospects appear positive as it addresses significant needs in patient compliance and therapy adherence.
Bears say
Vivani Medical Inc. faces significant risks that contribute to a negative outlook on its stock. The company’s lead product, NPM-139, is highly dependent on successful clinical trials and obtaining regulatory approval, both of which are uncertain and could hinder its path to market. Additionally, challenges related to market size, penetration rates, competition, and potential dilution further exacerbate the company's financial vulnerabilities and decrease investor confidence.
This aggregate rating is based on analysts' research of Vivani Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
VANI Analyst Forecast & Price Prediction
Start investing in VANI
Order type
Buy in
Order amount
Est. shares
0 shares